PD Drug Combination Therapy Matrix

📖 Wiki Page

therapeutic2773 wordssynced 2026-04-02

Parkinson's Disease Drug Combination Therapy Matrix

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PD Drug Combination Therapy Matrix</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>LED Factor</td>
</tr>
<tr>
<td class="label">Levodopa (standard)</td>
<td>1.0</td>
</tr>
<tr>
<td class="label">Levodopa (controlled-release)</td>
<td>0.75</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>100</td>
</tr>
<tr>
<td class="label">Ropinirole</td>
<td>20</td>
</tr>
<tr>
<td class="label">Rotigotine</td>
<td>15</td>
</tr>
<tr>
<td class="label">Apomorphine (injectable)</td>
<td>10</td>
</tr>
<tr>
<td class="label">Apomorphine (infusion)</td>
<td>6.5</td>
</tr>
<tr>
<td class="label">Agonist</td>
<td>Route</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Ropinirole</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Rotigotine</td>
<td>Transdermal</td>
</tr>
<tr>
<td class="label">Apomorphine</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td class="label">Piribedil</td>
<td>Oral</td>
</tr>
</table>

Introduction

...

Parkinson's Disease Drug Combination Therapy Matrix

Introduction

Mermaid diagram (expand to render)

The pharmacologic management of Parkinson's disease (PD) represents one of the most complex therapeutic challenges in neurology. Since the introduction of levodopa in the 1960s, clinicians have developed increasingly sophisticated strategies to manage the dual challenges of maintaining adequate dopaminergic stimulation while minimizing the motor complications that inevitably arise with long-term treatment. This matrix synthesizes evidence-based drug combinations used in contemporary PD management, their mechanisms of synergy, clinical evidence levels, and practical considerations for implementation.

The evolution of PD therapy has moved from simple levodopa monotherapy toward sophisticated multi-target approaches that address the diverse neurochemical deficits that characterize the disease. Modern combination therapy recognizes that PD involves not only dopaminergic degeneration but also dysfunction in non-dopaminergic systems including serotonergic, noradrenergic, cholinergic, and glutamatergic pathways. Effective management therefore requires strategic combinations that address these multiple systems while optimizing dopaminergic stimulation["@kalia2013"][@obeso2010].

The Scientific Basis for Combination Therapy

Limitations of Levodopa Monotherapy

While levodopa remains the gold standard for PD treatment, long-term use is complicated by the development of motor fluctuations and dyskinesias. These complications arise from multiple interrelated mechanisms that combination therapy aims to address[@marsden1994][@nutt1993].

Pharmacokinetic Factors:
Oral levodopa has a plasma half-life of only 60-90 minutes, necessitating frequent dosing to maintain therapeutic plasma concentrations. The resulting peaks and troughs in dopaminergic stimulation lead to the "on-off" phenomenon where patients experience alternating periods of good motor function and poor function. Additionally, the short half-life means that plasma concentrations fall below the therapeutic threshold overnight, contributing to morning akinesia and sleep disturbances[@nutt1993][@stocchi2012].

Pharmacodynamic Factors:
With disease progression, striatal dopaminergic terminals are progressively lost, reducing the capacity for dopamine storage and缓冲. This loss means patients become increasingly dependent on exogenous levodopa delivery and lose the ability to smooth out fluctuations in plasma concentrations. Furthermore, chronic pulsatile stimulation of dopamine receptors leads to downstream molecular changes including alterations in receptor expression, coupling, and downstream signaling pathways that contribute to dyskinesia development[@espay2014][@stocchi2010].

Continuous Dopaminergic Stimulation

The recognition that pulsatile stimulation underlies motor complications has driven the development of continuous dopaminergic stimulation (CDS) approaches. CDS aims to provide stable, around-the-clock dopaminergic receptor occupancy, mimicking the physiological pattern of dopamine release. This can be achieved through continuous drug delivery (infusion therapies) or through the use of long-acting drug formulations that provide more stable plasma concentrations[@stocchi2012][@chase1998].

Benefits of CDS:

Reduced motor fluctuations
Decreased dyskinesia severity
Improved quality of life
Potential disease-modifying effects
Better control of non-motor symptoms

Evidence for Disease Modification:
Some studies suggest that CDS may slow disease progression, possibly through reduction of oxidative stress, mitochondrial dysfunction, and protein aggregation. However, definitive evidence for disease modification remains elusive, and this potential benefit should not be the primary rationale for choosing combination therapy approaches[@schapira2013][@schapira2009].

Core Dopaminergic Combinations

Levodopa/Carbidopa: The Foundation

The combination of levodopa with the peripheral decarboxylase inhibitor carbidopa remains the cornerstone of PD pharmacotherapy. This combination was developed to address the peripheral side effects of levodopa including nausea, vomiting, and cardiovascular complications that arose when levodopa was administered alone[@lees2009].

Mechanism of Synergy:
Carbidopa inhibits aromatic L-amino acid decarboxylase (AADC) in peripheral tissues, preventing the conversion of levodopa to dopamine before it crosses the blood-brain barrier. This allows for lower levodopa doses while achieving equivalent or superior brain concentrations. The dose ratio of carbidopa to levodopa is typically 1:4 to 1:10, with most patients requiring 25-100 mg of carbidopa per dose of levodopa[@lees2009][@hauser2009].

Levodopa Equivalent Dose Calculations:
When combining levodopa/carbidopa with other dopaminergic agents, clinicians use levodopa equivalent doses (LED) to compare potencies:

Levodopa/Carbidopa/Entacapone: Extending Duration

The addition of entacapone to levodopa/carbidopa creates the first widely used combination approach specifically designed to extend levodopa's duration of action. Entacapone is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor that blocks the peripheral metabolism of levodopa, extending its plasma half-life by approximately 50-70%[@falconer2019][@schapira2000].

Mechanism of Synergy:
COMT is the primary pathway for peripheral levodopa metabolism, converting levodopa to 3-O-methyldopa (3-OMD). By inhibiting this pathway, entacapone increases the bioavailability of levodopa and extends its plasma concentration curve. This results in more consistent dopaminergic stimulation and reduced "off" time in patients with motor fluctuations[@falconer2019].

Clinical Evidence:
Multiple randomized controlled trials have demonstrated that adding entacapone to optimized levodopa/carbidopa therapy provides:

Reduction in "off" time: 1.2-1.7 hours/day
Increase in "on" time: 1.0-1.4 hours/day
Improved UPDRS motor scores
Reduced levodopa dose requirements
Improved quality of life measures

Dosing and Administration:
Entacapone is administered at 200 mg with each levodopa dose, up to a maximum of 8 tablets daily. The combination is available as a single-pill formulation (levodopa/carbidopa/entacapone) in various ratios, simplifying the regimen for patients with complex dosing requirements.

Levodopa/Carbidopa/Opicapone: Enhanced COMT Inhibition

Opicapone represents a newer generation of COMT inhibitors with enhanced potency and once-daily dosing convenience. Compared to entacapone, opicapone provides more sustained COMT inhibition and requires only single daily dosing with the first levodopa dose[@fischer2020].

Advantages over Entacapone:

More potent COMT inhibition (10-20x)
Once-daily dosing
No requirement for timing with each levodopa dose
Reduced pill burden
Superior reduction in "off" time in some trials

Clinical Evidence:
The BIPARK-I and BIPARK-II trials demonstrated that opicapone at 50 mg once daily provided statistically significant and clinically meaningful reductions in "off" time compared to placebo and non-inferiority to entacapone. Improvements were sustained through 52 weeks of open-label treatment.

Mechanistic Advantages:
Opicapone's long duration of action provides more consistent COMT inhibition throughout the day and night, addressing the overnight "off" periods that many patients experience. This may be particularly beneficial for patients with significant early morning akinesia.

Levodopa/MAO-B Inhibitor Combinations

Combining levodopa with monoamine oxidase B (MAO-B) inhibitors represents a cornerstone strategy for managing motor fluctuations. MAO-B inhibitors block the enzymatic breakdown of dopamine in the brain, extending the dopaminergic effect of each levodopa dose and providing additional symptom control beyond what levodopa alone can achieve[@schapira2000].

Available MAO-B Inhibitors:

Rasagiline: Once-daily, 1 mg dose, no dietary restrictions
Safinamide: Once-daily, 50-100 mg, requires titration
Selegiline: Twice-daily, 5-10 mg, requires dietary restrictions (tyramine)

Mechanism of Synergy:
MAO-B is the primary enzyme responsible for dopamine metabolism in the brain. By inhibiting this enzyme, MAO-B inhibitors increase synaptic dopamine concentrations and extend the duration of dopaminergic stimulation from each levodopa dose. This provides smoother, more continuous dopaminergic receptor activation compared to levodopa alone[@schapira2000][@stocchi2012].

Evidence for Combination Benefit:
Large clinical trials have demonstrated that adding rasagiline or safinamide to levodopa/carbidopa provides:

Additional reduction in "off" time (0.5-1.0 hours/day)
Improved motor scores
Reduced levodopa dose requirements
Improved activities of daily living
Reduced Unified Dyskinesia Rating Scale scores

Neuroprotective Potential:
Beyond symptomatic benefits, some evidence suggests that MAO-B inhibitors may provide disease-modifying effects through reduction of oxidative stress and oxidative dopamine metabolism. The delayed-start design trials of rasagiline suggested possible disease-modifying benefits, though the evidence remains controversial[@schapira2013].

Levodopa/Dopamine Agonist Combinations

Dopamine agonists directly stimulate dopamine receptors, providing dopaminergic activation that is partially independent of endogenous dopamine production and storage. Combining dopamine agonists with levodopa allows for lower levodopa doses while maintaining or improving symptom control, potentially reducing the risk of motor complications[@calandra2016][@stocchi2010].

Mechanism of Synergy:
Dopamine agonists have longer half-lives than levodopa and provide more stable dopaminergic receptor stimulation. When combined with levodopa, they "smooth out" the pharmacokinetic fluctuations inherent to levodopa therapy. Additionally, dopamine agonists may have preferential activity on specific dopamine receptor subtypes (D1 vs D2), providing different modulation of motor circuits compared to levodopa[@calandra2016].

Available Dopamine Agonists:

Clinical Evidence:
Combination therapy with dopamine agonists and levodopa provides:

Improved motor scores compared to levodopa alone
Reduced motor fluctuations
Lower levodopa dose requirements
Reduced dyskinesia severity at equivalent motor control

Practical Considerations:
Dopamine agonists are typically initiated at low doses and titrated gradually to minimize side effects including nausea, orthostatic hypotension, and somnolence. The transdermal rotigotine patch provides more stable plasma concentrations and may be particularly useful for patients with swallowing difficulties or gastrointestinal issues that limit oral absorption.

Adjunctive Therapies for Motor Complications

Istradefylline: Adenosine A2A Antagonism

Istradefylline is an adenosine A2A receptor antagonist approved as an adjunctive therapy for PD patients with motor fluctuations. This novel mechanism provides dopaminergic-like effects without direct dopamine receptor activation, offering a complementary approach to standard dopaminergic therapy.

Mechanism of Action:
Adenosine A2A receptors are highly expressed in the striatum, particularly in the indirect pathway of the basal ganglia motor circuit. Under normal conditions, adenosine A2A receptor activation inhibits motor execution through facilitation of the indirect pathway. Blocking these receptors reduces inhibitory output from the indirect pathway, enhancing motor execution in a manner that is synergistic with dopaminergic therapy.

Clinical Evidence:
The ISS051 and ISS003 trials demonstrated that istradefylline at 20-40 mg once daily provided:

Reduction in "off" time: 0.6-1.0 hours/day
Increase in "on" time: 0.5-0.8 hours/day
Improved motor scores
Well-tolerated with no worsening of dyskinesia

Mechanistic Advantages:
Unlike dopaminergic agents, A2A antagonism does not appear to induce or worsen dyskinesias, making it an attractive option for patients with prominent dyskinesia complications. The mechanism also does not interact with dopaminergic pathways in a way that would induce psychiatric side effects, and some studies suggest potential neuroprotective effects.

Amantadine: NMDA Antagonism for Dyskinesia

Amantadine, originally developed as an antiviral agent, provides unique benefits for PD patients with levodopa-induced dyskinesias. Its mechanism involves NMDA receptor antagonism within the basal ganglia, reducing the excessive glutamatergic signaling that contributes to dyskinesia development.

Mechanism of Synergy:
In PD with dyskinesia, there is excessive glutamatergic signaling through NMDA receptors in the striatum, contributing to the abnormal motor patterns characteristic of dyskinesias. Amantadine blocks these NMDA receptors, reducing the glutamergic drive and normalizing motor output. This effect is complementary to dopaminergic therapy and can reduce dyskinesia severity without compromising motor control.

Clinical Evidence:
Multiple randomized controlled trials have demonstrated that amantadine at 200-400 mg/day provides:

Reduction in dyskinesia severity: 30-50%
No deterioration in motor function
Possible improvement in "off" time
Benefits maintained for up to 2 years in open-label studies

Combination Considerations:
Amantadine can be combined with any dopaminergic therapy and is typically added when dyskinesias become problematic despite optimal dopaminergic management. The dose should be titrated slowly to minimize side effects including dizziness, insomnia, and livedo reticularis.

Clonazepam and Melatonin: Tremor Management

For tremor-dominant PD patients, adjunctive therapy with clonazepam (a benzodiazepine) or melatonin can provide additional tremor control without requiring adjustments to dopaminergic therapy.

Clonazepam:
Clonazepam provides tremor improvement through GABAergic modulation of thalamocortical circuits. Starting at 0.25-0.5 mg at bedtime, doses can be titrated up to 2-3 mg/day. Side effects include sedation, ataxia, and cognitive effects that may limit use in elderly patients.

Melatonin:
Melatonin has shown efficacy for PD tremor through unclear mechanisms that may involve circadian modulation and direct effects on motor circuits. Doses of 3-12 mg at bedtime provide tremor reduction in some patients with minimal side effects.

Advanced and Emerging Combinations

Triple Therapy: Levodopa + COMT + MAO-B

For patients with advanced disease and severe motor fluctuations, maximizing dopaminergic availability through multiple pathways can provide additional benefit. The combination of levodopa, a COMT inhibitor (entacapone or opicapone), and a MAO-B inhibitor (rasagiline or safinamide) represents the most comprehensive approach to optimizing dopaminergic stimulation.

Mechanistic Rationale:
This triple combination addresses dopaminergic metabolism at multiple levels:

Levodopa: Direct dopamine precursor
COMT inhibitor: Blocks peripheral levodopa breakdown
MAO-B inhibitor: Blocks central dopamine breakdown

This multi-target approach provides more complete inhibition of dopamine metabolism than any single agent or dual combination.

Clinical Evidence:
Observational studies suggest that triple therapy provides superior motor outcomes compared to dual combinations, with additional reductions in "off" time and improvements in "on" time. However, evidence from randomized controlled trials is limited, and the approach is considered off-label in many jurisdictions.

Genetic-Specific Combinations

As precision medicine approaches emerge, combinations targeting specific genetic causes of PD are being developed:

LRRK2 Inhibitor + GBA1 Modulator:
Patients with LRRK2 or GBA1 mutations have distinct pathogenic mechanisms involving lysosomal dysfunction. Combining LRRK2 inhibitors with GBA1 modulators (such as ambroxol) may provide synergistic benefits by addressing both pathways simultaneously.

Gene Therapy Combinations:
Viral vector delivery of genes encoding AADC (VY-AADC1), GAD (GAD1), or aromatic L-amino acid decarboxylase in combination with standard pharmacotherapy represents an emerging approach with potential for synergistic effects.

Multi-Pathway Approaches

Emerging combinations target multiple neurotransmitter systems beyond the dopaminergic system:

Alpha-synuclein + GLP-1 Receptor Agonist:
Combining anti-alpha-synuclein immunotherapies (like prasinezumab) with GLP-1 receptor agonists (like exenatide) may provide synergistic effects through protein clearance and neuroprotection pathways.

Iron Chelation + Anti-inflammatory:
For patients with prominent iron accumulation or neuroinflammation, combining iron chelators (like deferoxamine) with anti-inflammatory agents may address pathological axes beyond dopaminergic therapy.

Clinical Implementation Strategies

Principles of Combination Selection

When implementing combination therapy, clinicians should consider:

Disease Stage: Early disease may benefit from simpler combinations, while advanced disease often requires more comprehensive approaches

Motor Symptom Profile: Tremor-dominant, akinetic-rigid, and mixed phenotypes may respond differently to specific combinations

Non-motor Symptoms: Psychiatric, autonomic, and sleep symptoms may influence choice of specific agents

Patient Preferences: Pill burden, administration route, and lifestyle factors impact adherence

Comorbidities: Cardiovascular, renal, hepatic, and cognitive status affect drug selection

Age: Elderly patients may require modified dosing and may be more sensitive to side effects

Practical Dosing Strategies

Initiation:

Start with levodopa/carbidopa at doses sufficient to provide symptom control
Add adjunctive agents one at a time, starting at low doses
Allow adequate time to assess efficacy before adjusting or adding additional agents

Optimization:

Use patient diaries to assess "on" and "off" time
Adjust doses based on symptom control and side effect profile
Consider levodopa dose equivalence when combining agents
Monitor for peak-dose dyskinesia and adjust timing accordingly

Management of Side Effects:

Nausea: Prochlorperazine, domperidone, or dose adjustment
Orthostatic hypotension: Volume expansion, dose adjustment, fludrocortisone
Psychosis: Reduce dose, add pimavanserin or quetiapine
Impulse control disorders: Reduce or discontinue agonist, add naltrexone

External Links

[Parkinson's Foundation - Medication Guide](https://www.parkinson.org/living-with-parkinsons/treatment/medication)
[ClinicalTrials.gov - Parkinson's Disease Combination Therapy](https://clinicaltrials.gov/search?cond=parkinson+disease&intr=combination+therapy)
[International Parkinson's and Movement Disorders Society](https://www.mds.org/)

References

[Schapira AH, Neuroprotection in Parkinson's disease (2000)](https://pubmed.ncbi.nlm.nih.gov/10790039/)

[Jankovic J, Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations (2005)](https://pubmed.ncbi.nlm.nih.gov/15648270/)

[Stocchi F, Jenner P, Obeso JA, When do levodopa-induced dyskinesias begin? (2010)](https://pubmed.ncbi.nlm.nih.gov/20108233/)

[Falconer RA, Rogers SL, Friedrich J, et al, Levodopa/carbidopa/entacapone: a review of its use in the management of Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30868492/)

[Schapira AH, Olanow CW, Neuroprotection in Parkinson's disease: now, not when (2013)](https://pubmed.ncbi.nlm.nih.gov/23476326/)

[Marsden CD, Problems with long-term levodopa therapy for Parkinson's disease (1994)](https://pubmed.ncbi.nlm.nih.gov/7913298/)

[Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al, Missing pieces in the Parkinson's disease puzzle (2010)](https://pubmed.ncbi.nlm.nih.gov/20209082/)

[Poewe W, The natural history of Parkinson's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16782902/)

[Schapira AH, Complex I-targeted therapies for Parkinson's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19416954/)

[Chen J, Chen Y, Pu J, Mitochondria in neurodegenerative disorders: mechanism and therapeutic targets (2019)](https://pubmed.ncbi.nlm.nih.gov/30806981/)

[Kalia LV, Lang AE, Parkinson's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24057009/)

[Lees AJ, Hardie T, Stern GM, Levodopa: 40 years on (2009)](https://pubmed.ncbi.nlm.nih.gov/19487942/)

[Hauser RA, Levodopa: the master of movement and the curse of dyskinesia (2009)](https://pubmed.ncbi.nlm.nih.gov/19786840/)

[Nutt JG, Woodward WR, Hammerstad JP, et al, The on-off phenomenon in Parkinson's disease (1993)](https://pubmed.ncbi.nlm.nih.gov/7905708/)

[Chase TN, The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease (1998)](https://pubmed.ncbi.nlm.nih.gov/9633670/)

[Stocchi F, The therapeutic concept of continuous dopaminergic stimulation (CDS) in Parkinson's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22459824/)

[Rajput AH, Levodopa toxicity in Parkinson's disease: reality or myth? (2001)](https://pubmed.ncbi.nlm.nih.gov/11148241/)

[Espay AJ, Bruckmaier O, Liu M, et al, Levodopa-induced dyskinesia: clinical features, pathophysiology, and treatment (2014)](https://pubmed.ncbi.nlm.nih.gov/25002087/)

[Calandra C, Polidori L, Artusi CA, et al, Current strategies for treating Parkinson's disease: the role of early combination therapy (2016)](https://pubmed.ncbi.nlm.nih.gov/27326627/)

[Fischer C, Long K, Hanspal S, et al, A systematic review of real-world evidence for the management of motor fluctuations in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32248921/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Circadian-Synchronized Proteostasis Enhancement](/hypothesis/h-0e0cc0c1) — 0.67 · Target: CLOCK/ULK1
[Circadian Clock-Autophagy Synchronization](/hypothesis/h-b7898b79) — 0.67 · Target: CLOCK
[Temporal Decoupling via Circadian Clock Reset](/hypothesis/h-019ad538) — 0.65 · Target: CLOCK
[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — 0.72 · Target: BCL2L1

Related Analyses:

[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄

📖 View canonical wiki page →

PD Drug Combination Therapy Matrix

Parkinson's Disease Drug Combination Therapy Matrix

Introduction

Parkinson's Disease Drug Combination Therapy Matrix

Introduction

The Scientific Basis for Combination Therapy

Limitations of Levodopa Monotherapy

Continuous Dopaminergic Stimulation

Core Dopaminergic Combinations

Levodopa/Carbidopa: The Foundation

Levodopa/Carbidopa/Entacapone: Extending Duration

Levodopa/Carbidopa/Opicapone: Enhanced COMT Inhibition

Levodopa/MAO-B Inhibitor Combinations

Levodopa/Dopamine Agonist Combinations

Adjunctive Therapies for Motor Complications

Istradefylline: Adenosine A2A Antagonism

Amantadine: NMDA Antagonism for Dyskinesia

Clonazepam and Melatonin: Tremor Management

Advanced and Emerging Combinations

Triple Therapy: Levodopa + COMT + MAO-B

Genetic-Specific Combinations

Multi-Pathway Approaches

Clinical Implementation Strategies

Principles of Combination Selection

Practical Dosing Strategies

See Also

External Links

References

Related Hypotheses